Investment Centers of America Inc. bought a new stake in GW Pharmaceuticals PLC (NASDAQ:GWPH) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 4,193 shares of the biopharmaceutical company’s stock, valued at approximately $420,000.

Several other hedge funds have also modified their holdings of GWPH. BNP Paribas Arbitrage SA acquired a new stake in shares of GW Pharmaceuticals PLC in the 2nd quarter valued at $163,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of GW Pharmaceuticals PLC during the 2nd quarter valued at $204,000. Blair William & Co. IL acquired a new stake in shares of GW Pharmaceuticals PLC during the 1st quarter valued at $207,000. Ameriprise Financial Inc. boosted its holdings in shares of GW Pharmaceuticals PLC by 8.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 162 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in shares of GW Pharmaceuticals PLC during the 2nd quarter valued at $213,000. 75.06% of the stock is currently owned by hedge funds and other institutional investors.

GW Pharmaceuticals PLC (NASDAQ GWPH) opened at 108.23 on Monday. GW Pharmaceuticals PLC has a one year low of $92.65 and a one year high of $137.88. The firm’s market capitalization is $2.74 billion. The firm’s 50-day moving average price is $105.92 and its 200 day moving average price is $110.11.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same quarter in the previous year, the company earned ($0.05) earnings per share. On average, equities analysts anticipate that GW Pharmaceuticals PLC will post ($5.94) earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on the company. Maxim Group downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating and set a $61.00 price objective on the stock. in a report on Tuesday, August 8th. BidaskClub downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Leerink Swann reissued an “outperform” rating and set a $160.00 price objective (down previously from $162.00) on shares of GW Pharmaceuticals PLC in a report on Thursday, August 10th. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, Evercore ISI assumed coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $148.55.

ILLEGAL ACTIVITY WARNING: “Investment Centers of America Inc. Takes Position in GW Pharmaceuticals PLC (GWPH)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/18/investment-centers-of-america-inc-takes-position-in-gw-pharmaceuticals-plc-gwph.html.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.